Abpro Holdings (ABP) Registration Filing summary

Company overview and business model

• Focuses on developing next-generation antibody therapeutics for severe and life-threatening diseases, primarily in immuno-oncology and ophthalmology.

• Utilizes proprietary DiversImmune® and MultiMab™ platforms to generate and engineer novel antibody constructs.

• Lead candidates ABP-102 (HER2/CD3 T-cell engager for solid tumors) and ABP-201 (VEGF/ANG-2 inhibitor for ocular diseases) are in preclinical development, with clinical trials planned for 2026.

• Operates through collaborations with global pharmaceutical partners, including Celltrion and Abpro Bio.

• Business model includes licensing, milestone payments, royalties, and profit-sharing from partnered programs.

Financial performance and metrics

• Reported net loss of $7.2 million for 2024 and $3.9 million for Q1 2025; accumulated deficit reached $120 million as of March 31, 2025.

• Cash balance was $1.3 million as of March 31, 2025, with substantial doubt about ability to continue as a going concern for the next 12 months.

• Operating expenses in Q1 2025 were $3.0 million, with R&D expenses down 68% year-over-year due to furloughs and reduced activity.

• No material product revenue; limited revenue from research services and collaboration milestones.

• Restated prior financials due to errors in accrued expenses, impacting investor confidence.

Use of proceeds and capital allocation

• May receive up to $50 million in gross proceeds from sales of common stock to YA II PN, Ltd. under the Standby Equity Purchase Agreement (SEPA).

• Proceeds intended for working capital and general corporate purposes, with management retaining broad discretion over allocation.

• No assurance of full access to SEPA funds; actual proceeds depend on market conditions and share price.